Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

--Alliance designed to foster best in class cell therapy product and manufacturing innovation through risk-sharing and royalty-based model

BLUE : 25.41 (-0.97%)
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021

Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance...

BMY : 67.87 (-0.41%)
XLRN : 125.06 (-1.52%)
BLUE : 25.41 (-0.97%)
AGEN : 5.18 (-0.19%)
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.

IRWD : 13.27 (+0.84%)
BMY : 67.87 (-0.41%)
PFE : 42.81 (+0.05%)
BLUE : 25.41 (-0.97%)
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

/PRNewswire/ -- Former Attorney General of , , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE).  ...

BLUE : 25.41 (-0.97%)
bluebird bio Receives EC Approval for SKYSONA(TM) (elivaldogene autotemcel, Lenti-D(TM)) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

--CALD is a rare neurodegenerative disease that can lead to progressive, irreversible loss of neurologic function, and death

BLUE : 25.41 (-0.97%)
Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H

Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.

BMY : 67.87 (-0.41%)
PFE : 42.81 (+0.05%)
RGEN : 245.70 (+1.95%)
BLUE : 25.41 (-0.97%)
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO(TM) Gene Therapy for Transfusion-Dependent B-thalassemia and Marketing to Resume in EU

--Company has informed EMA of lift of voluntary temporary marketing suspension

BLUE : 25.41 (-0.97%)
Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma

Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.

BMY : 67.87 (-0.41%)
MRK : 76.87 (-0.08%)
RGEN : 245.70 (+1.95%)
BLUE : 25.41 (-0.97%)
Bristol Myers' (BMY) Onureg Gets European Commission Approval

Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.

BMY : 67.87 (-0.41%)
MRK : 76.87 (-0.08%)
RGEN : 245.70 (+1.95%)
BLUE : 25.41 (-0.97%)
Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate

Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).

BMY : 67.87 (-0.41%)
MRK : 76.87 (-0.08%)
RGEN : 245.70 (+1.95%)
BLUE : 25.41 (-0.97%)
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc....

BLUE : 25.41 (-0.97%)
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi

Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.

BMY : 67.87 (-0.41%)
MRK : 76.87 (-0.08%)
RGEN : 245.70 (+1.95%)
BLUE : 25.41 (-0.97%)
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for B-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual

--Across Phase 3 studies, 89% (32/36) of evaluable patients across ages and genotypes achieved TI and remain transfusion free, including 91% (20/22) of evaluable pediatric patients under the age of 18

BLUE : 25.41 (-0.97%)
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More

The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.

BIIB : 326.73 (-0.74%)
JNJ : 172.20 (+0.01%)
ALXN : 182.50 (+1.70%)
INCY : 77.35 (-0.06%)
BLUE : 25.41 (-0.97%)
ARGX : 304.43 (+2.90%)
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold

The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.

RGEN : 245.70 (+1.95%)
TECH : 482.24 (-0.18%)
BLUE : 25.41 (-0.97%)
KMDA : 5.44 (+0.37%)
bluebird bio to Present at Goldman Sachs Global Healthcare Conference

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET.

BLUE : 25.41 (-0.97%)
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and B-Thalassemia Studies

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for...

BLUE : 25.41 (-0.97%)
Why Is Bluebird (BLUE) Up 3.5% Since Last Earnings Report?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BLUE : 25.41 (-0.97%)
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 50,000 shares of...

BLUE : 25.41 (-0.97%)
bluebird bio Receives Positive CHMP Opinion for SKYSONA(TM) (elivaldogene autotemcel, Lenti-D(TM)) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)

--As of the data cutoff date, 90% of patients (27/30) treated with SKYSONA in the pivotal ALD-102 clinical study met the primary endpoint of major functional disability (MFD)-free survival at two years...

BLUE : 25.41 (-0.97%)

Barchart Exclusives

When Weather and Weather Derivatives Diverge
A look at the softs complex Friday morning shows us markets aren't looking at weather in Brazil to close out the month. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar